MetaCap

Kiniksa Pharmaceuticals International plc Class A (KNSA)

NASDAQ: KNSAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

93.90+0.36 (+0.38%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

KNSA stock chart

Technical analysis

Key statistics

All statistics
52-week range
37.02 – 99.31
Day range
92.68 – 95.29
Volume / Avg
545.14K / 664.53K
Beta
—

52-week range

$37.02$99.31

KNSA stock today

On Nov 20, KNSA ended the session at $93.90, adding $0.36 (0.38%), versus the S&P 500's 3.70% decline. Shares are 5.5% below their 52-week high of $99.31, set on Nov 9, 2026 and 153.6% above the 52-week low of $37.02, near the top of the past year's range. KNSA is up 127.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 125.8%.

At 71.1x trailing earnings, Kiniksa Pharmaceuticals International trades above the peer-group median of 47.8x. Its forward P/E of 45.9x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.

Summary generated from market data by MetaCap's automated system. Methodology

About Kiniksa Pharmaceuticals International

Company profile

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Sanjiv K. Patel
Headquarters
London
Employees
366
IPO year
2018

Financial highlights

Full financials

In fiscal 2025, Kiniksa Pharmaceuticals International generated $677.6 million in revenue, up 60.1% from fiscal 2024, its 4th consecutive year of revenue growth. Net income was $59.0 million, for a net margin of 8.7% versus a median of -2.5% in the prior 5 years. Gross margin was 88.5% (up from 85.6%) and operating margin 11.4%.

Kiniksa Pharmaceuticals International annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$677.56M$423.24M$270.26M$220.18M$38.54M
Growth+60.09%+56.60%+22.74%+471.24%—
Net income$59.01M$-43.19M$14.08M$183.36M$-157.92M
EPS (diluted)$0.75$-0.60$0.20$2.60$-2.30

Analyst forecast

Forecast

Consensus (7 analysts)

strong_buy

Avg. price target

$111.57+18.82%

  • Strong buy 1
  • Buy 6
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $98.00High $134.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 27, 2026
EPS actual vs est.
$0.56 vs $0.32
Surprise
+75.00%

KNSA news

All KNSA news

Kiniksa Pharmaceuticals International peers

Health Care sector
KNSA peer companies
CompanyPrice% ChgMarket capCompare
AMRXAmneal Pharmaceuticals Inc. Class A21.12-1.26%$7.36Bvs KNSA
ALKSAlkermes plc44.94-2.69%$7.55Bvs KNSA
CYTKCytokinetics Incorporated50.78-1.32%$7.07Bvs KNSA
CORTCorcept Therapeutics Incorporated63.62-2.09%$6.96Bvs KNSA
RYTMRhythm Pharmaceuticals Inc.112.36-3.80%$7.79Bvs KNSA
AXSMAxsome Therapeutics Inc.129.36-4.66%$6.80Bvs KNSA
PTGXProtagonist Therapeutics Inc.121.40-2.11%$7.92Bvs KNSA
SMMTSummit Therapeutics Inc.9.95-5.87%$7.96Bvs KNSA

Indexes, lists and sector

Kiniksa Pharmaceuticals International stock FAQ

What is Kiniksa Pharmaceuticals International's stock price today?

KNSA last traded at $93.90 as of Nov 20, 4:00 PM EST, up 0.38% on the day. Prices are delayed at least 15 minutes.

What is KNSA's P/E ratio?

KNSA trades at a trailing P/E ratio of 71.13 and a forward P/E of 45.91, compared with a median of 47.8 for its closest peers.

Who is Kiniksa Pharmaceuticals International's CEO?

Mr. Sanjiv K. Patel is the chief executive officer of Kiniksa Pharmaceuticals International plc Class A, which has about 366 employees.

What is the KNSA 52-week high?

The 52-week high for KNSA is $99.31 and the 52-week low is $37.02. The stock is currently 5.5% below its high.

Compare KNSA